A multi-glycoprotein synergized recombinant virus system resolved the research dilemma of Epstein-Barr virus entry and facilitated the development of entry-specific drugs or vaccines

This publication has 57 references indexed in Scilit:

• Structural basis for complement receptor engagement and virus neutralization through Epstein-Barr virus gp350
  Immunity, 2025
• Optimization and validation of a virus‐like particle pseudotyped virus neutralization assay for SARS‐CoV‐2
  Medcomm, 2024
• Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition
  Immunity, 2022
• Epstein-Barr virus: Biology and clinical disease
  Cell, 2022
• EBV associated T‐ and NK‐cell lymphoproliferative diseases: A comprehensive overview of clinical manifestations and novel therapeutic insights
  Reviews in Medical Virology, 2022
• The Application of a Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus
  Virologica Sinica, 2021
• An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus
  Immunity, 2018
• The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment
  Current Hematologic Malignancy Reports, 2015
• Different Functional Domains in the Cytoplasmic Tail of Glycoprotein B Are Involved in Epstein–Barr Virus-Induced Membrane Fusion
  Virology, 2001
• Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus
  International Journal of Cancer, 1999